ClinicalTrials.gg
CompletedNCT01185873Updated Nov 2, 2016

A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment

A Phase 1 interventional study of danoprevir and ritonavir in Healthy Volunteer, sponsored by Hoffmann-La Roche. Completed at 5 sites in 3 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
81
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This non-randomized, multi-center, open-label study will evaluate the pharmacokinetics and the safety and tolerability of danoprevir (RO5190591) and ritonavir in healthy volunteers and patients with mild, moderate or severe hepatic impairment. Participants will be administered repeated daily doses of danoprevir and ritonavir. The anticipated time on study treatment is 10 days.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Volunteers:

  • Adult healthy volunteers, 18-70 years of age
  • Weight >/=50.0 kg
  • (BMI) 18.0-40.0 kg/m2
  • Ability and willingness to abstain from alcohol-containing beverages or food from 48 hours prior to entry in the clinical study center until discharge
  • Ability and willingness to abstain from grapefruit or grapefruit juice, star fruit, and Seville oranges from 7 days prior to entry in the clinical study center until discharge
  • Medical history without major recent or ongoing pathology

Patients with hepatic impairment:

  • Adult patients, 18-70 years of age
  • Weight >/=50.0 kg
  • Body Mass Index (BMI) 18.0-40.0 kg/m2
  • Ability and willingness to abstain from alcohol-containing beverages or food from 48 hours prior to entry in the clinical study center until discharge
  • Ability and willingness to abstain from grapefruit or grapefruit juice, star fruit, and Seville oranges from 7 days prior to entry in the clinical study center until discharge
  • Stable, mild, moderate, or severe liver disease of cryptogenic, post-hepatic, or alcoholic origin

Exclusion criteria

Exclusion Criteria:

Healthy Volunteers:

  • Pregnant or lactating women and male partners of women who are pregnant or lactating
  • Uncontrolled treated/untreated hypertension (systolic blood pressure >/=160 mmHg and /or diastolic blood pressure >/=105 mmHg
  • Any history of cardiovascular or cerebrovascular disease
  • \</=60 mL/min
  • Positive test results for drugs or alcohol
  • Donation or loss of blood over 450 ml within 60 days prior to screening

Patients with hepatic impairment:

  • Pregnant or lactating women and male partners of women who are pregnant or lactating
  • Uncontrolled treated/untreated hypertension (systolic blood pressure >/=160 mmHg and /or diastolic blood pressure >/=105 mmHg
  • Any history of clinically significant cardiovascular or cerebrovascular disease
  • Severe ascites at screening or admission to the clinic
  • History of or current severe hepatic encephalopathy (grade 3 or higher)
  • Any evidence of progressive liver disease within the last 4 weeks
  • History of liver transplantation
  • Creatinine clearance \</=60 mL/min
  • Positive test results for drugs or alcohol
  • Donation or loss of blood over 450 ml within 60 days prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    1

    Drug: danoprevir · Drug: ritonavir

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (plasma concentration) of danoprevir in patients with hepatic impairment

    Time frame: From baseline to day 10

Secondary outcomes

  1. Safety and tolerability (incidence of adverse events) of danoprevir in patients with hepatic impairment

    Time frame: From baseline to day 10

07

Study locations

5 sites
  • Lenexa, Kansas 66219, United States
  • Prague 8, 180 00, Czech Republic
  • Praha 7, 170 00, Czech Republic
  • Bratislava, 831 01, Slovakia
  • Bratislava, 83305, Slovakia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2010
First posted
Aug 20, 2010
Start
Feb 2011
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01185873
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 20, 2010
Start date
Feb 2011
Primary completion
Dec 2013
Completion
Dec 2013
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Danoprevir · Ritonavir

Start the discussion